Results 181 to 190 of about 427 (275)

Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report

Clinical Transplantation, Volume 40, Issue 6, June 2026.
ABSTRACT Introduction The effects of induction therapy with the anti‐CD52 monoclonal antibody alemtuzumab on age‐specific outcomes following kidney transplantation (KT) remain inadequately studied. This study aimed to analyze the comparative safety and efficacy of single‐dose alemtuzumab induction in deceased donor (DD) KT recipients according to ...
Alex Ng, David I. Harriman, Alan C. Farney, Giuseppe Orlando, Colleen Jay, Amber Reeves‐Daniel, Robert J. Stratta   +6 more
wiley   +1 more source

“Mycophenolate‐Based Immunosuppression After Calcineurin‐Inhibitor Withdrawal in Liver Transplant Recipients is Safe and Results in Long‐Term Improvement in Renal Function”

Clinical Transplantation, Volume 40, Issue 6, June 2026.
ABSTRACT Introduction Renal dysfunction is an important side effect of calcineurin inhibitors (CNI) and is associated with worse outcomes after liver transplantation (LT). Prior studies on mycophenolate‐based (MMF), CNI‐free immunosuppression regimens have raised concerns about the risk of rejection (ACR).
Nicholas Lim, David Vock, Scott Jackson, John Lake   +3 more
wiley   +1 more source

Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature. [PDF]

PLoS One, 2017
Kormann R, François H, Moles T, Dantal J, Kamar N, Moreau K, Bachelet T, Heng AE, Garstka A, Colosio C, Ducloux D, Sayegh J, Savenkoff B, Viglietti D, Sberro R, Rondeau E, Peltier J.   +16 more
europepmc   +1 more source

Management of Gram‐Negative Bloodstream Infections With Oral Antibiotics in Solid Organ Transplant Recipients

Clinical Transplantation, Volume 40, Issue 6, June 2026.
ABSTRACT Background Transitioning from intravenous (IV) to oral antibiotics upon clinical stability in gram‐negative rod (GNR) bloodstream infections (BSI) in immunocompetent patients is effective, with comparable clinical success rates as IV therapy. Studies have historically excluded solid organ transplant (SOT) recipients.
Olubusola Fowowe, Taylor Morrisette, Aaron Hamby, Krutika Mediwala Hornback, Kelsey Coffman, Lindsay Deloney, Rodericks Fobbs, Alexandra Mills, Courtney Harris, Rachel Burgoon   +9 more
wiley   +1 more source

[Infections in immunocompromised patients (II). The transplanted patient]. [PDF]

Medicine (Baltimore), 2018
Ramos Martínez A, Pintos Pascual I, Múñez Rubio E.   +2 more
europepmc   +1 more source

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4975-4990, June 2026.
ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna, Carlos Mena‐Hurtado, Victoria Divino, Zhenxiang Zhao, Yan Chen, Joanna Boland, Jinlin Song, Andrea Traina, Kerem Ozer, Filip K. Knop, Kim G. Smolderen   +10 more
wiley   +1 more source

Immune Landscape and Tumour Heterogeneity in Ovarian Cancer: Insights From Single‐Cell RNA Sequencing

Journal of Cellular and Molecular Medicine, Volume 30, Issue 11, June 2026.
ABSTRACT Tumour heterogeneity is a key factor in cancer progression, with immune responses within the tumour microenvironment (TME) contributing significantly to treatment resistance and immunotherapy outcomes. Recent advances in single‐cell RNA sequencing (scRNA‐seq) have provided unprecedented insights into the diverse immune cell populations ...
Sihan Chen, Ghada Moh. Samir Elhessewi, Helen Cai, Wedad M. Alawad, Manoj Kumar Mishra, Usamah Sayed   +5 more
wiley   +1 more source

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)]. [PDF]

Rev Neurol
Fernández O, Montalbán X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A.   +23 more
europepmc   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

One year in: early European adoption of the da Vinci Single Port platform—a multi‐institutional study from the European Association of Urology Robotic Urology Section Scientific Working Group

BJU International, Volume 137, Issue 6, Page 975-978, June 2026.
Francesco Pellegrino, Antony Pellegrino, Ugo Giovanni Falagario, Marco Tozzi, Robin Weston, Vishwanath Hanchanale, Giorgio Gandaglia, Alberto Briganti, Francesco Montorsi, Gabriele Tuderti, Aldo Brassetti, Giuseppe Simone, Alessandro Izzo, Gianluca Spena, Roberto Contieri, Sisto Perdonà, Alessandro Tedde, Massimo Madonia, Stefano Tappero, Elio Mazzone, Paolo Dell'Oglio, Antonio Galfano, Karel Decaestecker, Peter Dekuyper, Filip Ameye, Federico Lavagno, Giancarlo Marra, Paolo Gontero, Carlo Costi, Giovanni Passaretti, Antonio Russo, Franco Gaboardi, Axel Möller, Fredrik Sundquist, Mats Olsson, Chiara Vaccaro, Francesco Alessandro Mistretta, Stefano Luzzago, Gennaro Musi, Andrea Piccolini, Marco Paciotti, Giovanni Lughezzani, Nicolò Maria Buffi, Enrico Checcucci, Paolo Alessio, Daniele Amparore, Francesco Porpiglia, Filippo Marino, Luca Di Gianfrancesco, Davide De Marchi, Angelo Porreca, Christian Fankhauser, Matteo Ferro, Alberto Breda, Simone Crivellaro, Peter Wiklund, on behalf of the ERUS Scientific Working Group   +56 more
wiley   +1 more source